On December 27, 2024, John Kelly, Chief Financial Officer of Precision BioSciences Inc, purchased 2,113 shares of the company. Following this transaction, the insider now owns a total of 40,186 shares. The transaction details can be found in the SEC Filing. Precision BioSciences Inc (DTIL, Financial) is a biotechnology company focused on developing genome editing technologies to treat genetic disorders and cancers. The company aims to provide innovative solutions in the field of precision medicine. The insider's recent purchase is part of a broader trend within the company. Over the past year, there have been four insider buys and thirteen insider sells. This indicates a mixed sentiment among insiders regarding the company's stock.
On the day of the purchase, shares of Precision BioSciences Inc were trading at $4.75, giving the company a market cap of $32.679 million. The company's price-earnings ratio stands at 71.00, which is higher than the industry median of 25.97 and also higher than the company's historical median price-earnings ratio. The GF Value of Precision BioSciences Inc is estimated at $14.38, resulting in a price-to-GF-Value ratio of 0.33. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company's past returns and growth, as well as future estimates of business performance from Morningstar analysts.This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.